Full Text Full Text (PDF) Correction (v162,p644) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Simpson, G. M. Articles by Siu, C. O. Search for Related Content PubMed Citation Articles by Simpson, G. M. Articles by Siu, C. O. Atypical Neuroleptics Schizophrenia Spectrum Disorders

Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder

OBJECTIVE: Limited randomized, controlled trial data exist on possible differences between atypical antipsychotics in efficacy, overall tolerability, and important indices of health status. The authors compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely ill inpatients with schizophrenia or schizoaffective disorder. METHOD: In this 6-week, multicenter, double-blind, parallel-design, flexible-dose trial, patients were randomly assigned to receive ziprasidone (N=136) or olanzapine (N=133). Primary efficacy measures were improvement in Brief Psychiatric Rating Scale and Clinical Global Impression (CGI) severity scale scores; secondary measures were scores on the CGI improvement scale, Positive and Negative Syndrome Scale, and Calgary Depression Scale for Schizophrenia. Tolerability assessments included fasting lipid profiles, fasting glucose and insulin measurements, electrocardiography, and monitoring of vital signs and body weight. RESULTS: The overall mean daily doses were 129.9 mg (SD=27.3) for ziprasidone and 11.3 mg (SD=2.8) for olanzapine. Both antipsychotics were efficacious in improving symptoms and global illness severity. The two treatment groups did not differ significantly in primary or secondary efficacy measures at endpoint or in by-visit analysis. Both agents were well tolerated. Body weight, total cholesterol, triglycerides, and low-density lipoprotein cholesterol significantly increased with olanzapine but not with ziprasidone; all between-group comparisons of these variables were significant and favored ziprasidone. Olanzapine, but not ziprasidone, was associated with significant increases in fasting insulin level. No patient in either group exhibited a corrected QT interval 500 msec. CONCLUSIONS: During 6 weeks’ treatment, ziprasidone and olanzapine demonstrated comparable antipsychotic efficacy. Differences favoring ziprasidone were observed in metabolic parameters.

This article has been cited by other articles:

				D. Dickinson and P. D. Harvey Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem Schizophr Bull, August 9, 2008; (2008) sbn097v1. [Abstract] [Full Text] [PDF]

				S. Leucht, S. Heres, J. Hamann, and J. M. Kane Methodological Issues in Current Antipsychotic Drug Trials Schizophr Bull, March 1, 2008; 34(2): 275 - 285. [Abstract] [Full Text] [PDF]

				J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features Schizophr Bull, February 26, 2008; (2008) sbn005v1. [Abstract] [Full Text] [PDF]

				G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis Arch Gen Psychiatry, December 1, 2005; 62(12): 1305 - 1312. [Abstract] [Full Text] [PDF]

				P. Haddad Weight change with atypical antipsychotics in the treatment of schizophrenia J Psychopharmacol, November 1, 2005; 19(6_suppl): 16 - 27. [Abstract] [PDF]

				R. I. G. Holt, C. Bushe, and L. Citrome Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol, November 1, 2005; 19(6_suppl): 56 - 65. [Abstract] [PDF]

				R. M. CARNAHAN and P. J. PERRY Methodological Concerns in a Trial of Ziprasidone and Olanzapine Am J Psychiatry, July 1, 2005; 162(7): 1391 - 1391. [Full Text] [PDF]

				Other articles noted Evid. Based Ment. Health, May 1, 2005; 8(2): 32 - 32. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us